Orexo AB – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Orexo AB - Product Pipeline Review - H2 2011” provides data on the Orexo AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Orexo AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Orexo AB and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Orexo AB - Product Pipeline Review - H2 2011” provides data on the Orexo AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Orexo AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Orexo AB and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Orexo AB - Brief Orexo AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Orexo AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Orexo AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Orexo AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Orexo AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Orexo AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Orexo AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Orexo AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Orexo AB and identify potential opportunities in those areas.
Orexo AB Snapshot
Orexo AB Overview
Key Information
Key Facts
Orexo AB – Research and Development Overview
Key Therapeutic Areas
Orexo AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Orexo AB – Pipeline Products Glance
Orexo AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Orexo AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Orexo AB–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Orexo AB – Drug Profiles
Abstral
Product Description
Mechanism of Action
R&D Progress
OX219
Product Description
Mechanism of Action
R&D Progress
OX27
Product Description
Mechanism of Action
R&D Progress
OX30
Product Description
Mechanism of Action
R&D Progress
OX914
Product Description
Mechanism of Action
R&D Progress
Orexo AB – Pipeline Analysis
Orexo AB – Pipeline Products by Therapeutic Class
Orexo AB - Pipeline Products By Target
Orexo AB – Pipeline Products by Route of Administration
Orexo AB – Pipeline Products by Molecule Type
Orexo AB – Recent Pipeline Updates
Orexo AB - Dormant Projects
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2008: Orexo AB Announces That UK Medicines And Healthcare Products Regulatory Agency (MHRA) Issued UK Marketing Approval For Abstral
Oct 31, 2008: Orexo and ProStrakan advance date for taking over rights for Rapinyl in North America
Jul 31, 2008: Orexo and ProStrakan Extend Licensing Agreement for Rapinyl/Abstral and change Partner in North America
Jul 31, 2008: ProStrakan and Orexo Extend Licensing Agreement for Rapinyl/Abstral to include North America
Mar 31, 2011: Orexo Announces Successful Completion Of First Clinical Trial In OX51
Jun 30, 2009: Orexo announces that Abstral is ready for launch in France
Jun 30, 2009: Orexo Announces That Abstral Is Ready For Launch In France
Jun 30, 2009: ProStrakan Announces Upcoming Launch of Abstral in France
Apr 29, 2008: Orexo Reports Positive Results From Phase I Study For OX19
Aug 27, 2010: Orexo's Partner Kyowa Hakko Kirin To Conduct Additional Clinical Trials On KW-2246 For Treatment Of Cancer Pain In Japan
Jun 27, 2008: Positive CHMP Opinion for Abstral (Rapinyl)
Jan 27, 2009: Orexo signs agreement for Abstral in China
Jun 26, 2008: Orexo Reports Abstral (Rapinyl) Approval In Europe
Oct 25, 2007: Orexo signs distribution agreement with Hospira in Asia for pain product Rapinyl
Jul 25, 2006: ProSt rakan announces an exclusive agreement w ith Gedeon Richter to dist r ibute Rapinyl in CEE
Feb 25, 2010: Orexo announces Kyowa Hakko Kirin’s submission of KW-2246 (Abstral) for approval in Japan
Jul 24, 2009: Orexo Announces Positive Phase III Results For KW-2246 In Japan
Mar 24, 2009: Orexo Announces Clinical Results From An Experimental Phase IIa Study Of OX914
Sep 23, 2008: UK Marketing Approval Issued for Abstral
Dec 22, 2008: ProStrakan Announces Outlicensing of Abstral and Sancuso in Canada
Feb 22, 2011: Paladin Labs Obtains Canadian Approval For Abstral
Dec 21, 2005: ProSt rakan Group plc I n- licensing of European Rights to Rapinyl and Pre- close Period Trading Update
Sep 21, 2011: Orexo Announces Positive Results Supporting OX219 For Treatment Of Opioid Dependence
Aug 20, 2010: Orexo Announces Progress Of Phase I Trial Of OX27 In Cancer Pain
Aug 20, 2010: Orexo Starts Dosing In Phase I Clinical Study Of OX219 In Treating Opioid Addiction
Aug 20, 2010: Orexo To Initiate Phase I Clinical Trial Of OX51 For Treating Intense Pain Episodes In Opioid Tolerant And Opioid-Naive Patients
Dec 19, 2006: Orexo Announces Distribution agreement For Its Pain Product Rapinyl
May 18, 2010: Orexo reports continued strong Abstral sales in Europe
Feb 18, 2009: Orexo signs agreement for Abstral in Israel
Dec 17, 2007: Orexo´s partner Endo announces positive results from interim analysis of Rapinyl phase III clinical trial
Dec 17, 2007: Positive US Phase III Interim Data on Rapinyl Released by Endo Pharmaceuticals Inc
Nov 16, 2010: Orexo announces new sales figures for Abstral from its partner ProStrakan and updates on the US approval
Sep 16, 2010: Orexo signs agreement for Abstral for the Middle East and Africa
Dec 14, 2010: Orexo Reports Positive Phase I Trial Results Of OX219 In Opioid Dependence
Jun 14, 2011: Orexo Announces Successful Completion Of First Clinical Trial With OX27
Jun 14, 2011: Paladin Labs Announces Canadian Launch Of Abstral
Jan 14, 2010: Orexo and Invida jointly announce agreement for Abstral in Asia Pacific
Dec 11, 2008: Abstral Receives Marketing Approval In Germany
Jan 10, 2011: FDA Approval for Abstral (Fentanyl) Sublingual Tablets - US launch planned for Q1 2011
Jan 10, 2011: ProStrakan Receives FDA Approval For Cancer Pain Drug
Jan 10, 2008: Orexo Discloses New Mechanism For Asthma And COPD Treatment
Sep 07, 2010: Update on the FDA review for Abstral
Mar 07, 2008: Rapinyl Receives Swedish Marketing Authorization
Jan 07, 2010: Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe
Sep 06, 2009: ProStrakan Announces FDA Acceptance Of Abstral Filing in the US
Aug 06, 2009: Abstral file submitted to the FDA for approval in the USA
Apr 04, 2011: ProStrakan Launches Abstral In US
Feb 04, 2010: ProStrakan Announces Canadian Regulatory Filing Of Abstral
Sep 02, 2008: Orexo Initiates Clinical Phase II Program For OX914 - A New Product Candidate For The Treatment Of Inflammatory Airway Diseases
Jun 02, 2010: Abstral PDUFA Date Update
Jun 02, 2010: Orexo confirms Abstral PDUFA date update
Mar 02, 2009: Orexo’s Abstral Receives Two Further Large EU Market Approvals In France Aand Spain
Nov 01, 2007: Endo announces update on Phase III-program for Orexo´s pain product Rapinyl
Aug 01, 2007: ProStrakan Launches Nordic Sales Joint Venture with Orexo
Financial Deals Landscape
Orexo AB, Deals Summary
Orexo AB, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Biolipox Acquires Research And Development Assets From Inflazyme Pharmaceuticals
Venture Financing
PharmaKodex Secures $13.43 Million In Series A Financing
Biolipox Secures $41 Million In Series C Financing
Partnerships
Orexo Extends Licensing Agreement With Boehringer
Orexo Enters Into A Co-Development Agreement With Healthcare Company
Orexo Enters Into Co-Marketing Agreement With Hospira
ProStrakan Forms Joint Venture With Orexo
Gedeon Richter Enters Into A Distribution Agreement With Orexo
Doxa Enters Into Co-Development Agreement With Orexo
Licensing Agreements
Orexo Enters Into Licensing Agreement With NovaMed
Orexo Enters Into Licensing Agreement With Invida Group For Abstral
Orexo Enters Into Licensing Agreement With NewBridge Pharmaceuticals For Abstral
Orexo Enters Into Licensing Agreement With Ortho-McNeil-Janssen And Janssen Pharmaceutica
Orexo Enters Into Licensing Agreement With Novartis Pharmaceuticals
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With Orexo
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Endo Pharmaceuticals Enters Into Licensing Agreement With Orexo
Equity Offering
Orexo Completes Rights Issue Of $40 Million
Orexo Completes Initial Public Offering Of $41 Million
Orexo Completes Private Placement Of $7 Million
Debt Offering
Orexo Completes Private Placement Of Convertible Bonds For $15.4 Million
Asset Transactions
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Acquisition
Kibion Acquires Wagner Analysen Technik
Orexo Acquires PharmaKodex
Orexo Acquires Biolipox
Kibion Acquires Noster System
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Orexo AB – Pipeline by Therapy Area and Indication, H2 2011
Orexo AB – Pipeline by Stage of Development, H2 2011
Orexo AB – Monotherapy Products in Pipeline, H2 2011
Orexo AB – Filed, H2 2011
Orexo AB – Phase III, H2 2011
Orexo AB - Phase II, H2 2011
Orexo AB - Phase I, H2 2011
Orexo AB - Pipeline By Therapeutic Class, H2 2011
Orexo AB - Pipeline By Target, H2 2011
Orexo AB – Pipeline By Route of Administration, H2 2011
Orexo AB – Pipeline By Molecule Type, H2 2011
Orexo AB – Recent Pipeline Updates, H2 2011
Orexo AB - Dormant Developmental Projects, 2010
Orexo AB, Subsidiaries
Orexo AB, Deals Summary
Biolipox Acquires Research And Development Assets From Inflazyme Pharmaceuticals
PharmaKodex Secures $13.43 Million In Series A Financing
Biolipox Secures $41 Million In Series C Financing
Orexo Extends Licensing Agreement With Boehringer
Orexo Enters Into A Co-Development Agreement With Healthcare Company
Orexo Enters Into Co-Marketing Agreement With Hospira
ProStrakan Forms Joint Venture With Orexo
Gedeon Richter Enters Into A Distribution Agreement With Orexo
Doxa Enters Into Co-Development Agreement With Orexo
Orexo Enters Into Licensing Agreement With NovaMed
Orexo Enters Into Licensing Agreement With Invida Group For Abstral
Orexo Enters Into Licensing Agreement With NewBridge Pharmaceuticals For Abstral
Orexo Enters Into Licensing Agreement With Ortho-McNeil-Janssen And Janssen Pharmaceutica
Orexo Enters Into Licensing Agreement With Novartis Pharmaceuticals
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With Orexo
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Endo Pharmaceuticals Enters Into Licensing Agreement With Orexo
Orexo Completes Rights Issue Of $40 Million
Orexo Completes Initial Public Offering Of $41 Million
Orexo Completes Private Placement Of $7 Million
Orexo Completes Private Placement Of Convertible Bonds For $15.4 Million
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Kibion Acquires Wagner Analysen Technik
Orexo Acquires PharmaKodex
Orexo Acquires Biolipox
Kibion Acquires Noster System
LIST OF FIGURES
Orexo AB – Pipeline by Therapy Area and Indication, H2 2011
Orexo AB – Pipeline by Stage of Development, H2 2011
Orexo AB – Monotherapy Products in Pipeline, H2 2011
Orexo AB – Pipeline By Therapeutic Class, H2 2011
Orexo AB - Pipeline By Target, H2 2011
Orexo AB – Pipeline By Route of Administration, H2 2011
Orexo AB – Pipeline By Molecule Type, H2 2011
Orexo AB Overview
Key Information
Key Facts
Orexo AB – Research and Development Overview
Key Therapeutic Areas
Orexo AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Orexo AB – Pipeline Products Glance
Orexo AB – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Orexo AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Orexo AB–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Orexo AB – Drug Profiles
Abstral
Product Description
Mechanism of Action
R&D Progress
OX219
Product Description
Mechanism of Action
R&D Progress
OX27
Product Description
Mechanism of Action
R&D Progress
OX30
Product Description
Mechanism of Action
R&D Progress
OX914
Product Description
Mechanism of Action
R&D Progress
Orexo AB – Pipeline Analysis
Orexo AB – Pipeline Products by Therapeutic Class
Orexo AB - Pipeline Products By Target
Orexo AB – Pipeline Products by Route of Administration
Orexo AB – Pipeline Products by Molecule Type
Orexo AB – Recent Pipeline Updates
Orexo AB - Dormant Projects
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2008: Orexo AB Announces That UK Medicines And Healthcare Products Regulatory Agency (MHRA) Issued UK Marketing Approval For Abstral
Oct 31, 2008: Orexo and ProStrakan advance date for taking over rights for Rapinyl in North America
Jul 31, 2008: Orexo and ProStrakan Extend Licensing Agreement for Rapinyl/Abstral and change Partner in North America
Jul 31, 2008: ProStrakan and Orexo Extend Licensing Agreement for Rapinyl/Abstral to include North America
Mar 31, 2011: Orexo Announces Successful Completion Of First Clinical Trial In OX51
Jun 30, 2009: Orexo announces that Abstral is ready for launch in France
Jun 30, 2009: Orexo Announces That Abstral Is Ready For Launch In France
Jun 30, 2009: ProStrakan Announces Upcoming Launch of Abstral in France
Apr 29, 2008: Orexo Reports Positive Results From Phase I Study For OX19
Aug 27, 2010: Orexo's Partner Kyowa Hakko Kirin To Conduct Additional Clinical Trials On KW-2246 For Treatment Of Cancer Pain In Japan
Jun 27, 2008: Positive CHMP Opinion for Abstral (Rapinyl)
Jan 27, 2009: Orexo signs agreement for Abstral in China
Jun 26, 2008: Orexo Reports Abstral (Rapinyl) Approval In Europe
Oct 25, 2007: Orexo signs distribution agreement with Hospira in Asia for pain product Rapinyl
Jul 25, 2006: ProSt rakan announces an exclusive agreement w ith Gedeon Richter to dist r ibute Rapinyl in CEE
Feb 25, 2010: Orexo announces Kyowa Hakko Kirin’s submission of KW-2246 (Abstral) for approval in Japan
Jul 24, 2009: Orexo Announces Positive Phase III Results For KW-2246 In Japan
Mar 24, 2009: Orexo Announces Clinical Results From An Experimental Phase IIa Study Of OX914
Sep 23, 2008: UK Marketing Approval Issued for Abstral
Dec 22, 2008: ProStrakan Announces Outlicensing of Abstral and Sancuso in Canada
Feb 22, 2011: Paladin Labs Obtains Canadian Approval For Abstral
Dec 21, 2005: ProSt rakan Group plc I n- licensing of European Rights to Rapinyl and Pre- close Period Trading Update
Sep 21, 2011: Orexo Announces Positive Results Supporting OX219 For Treatment Of Opioid Dependence
Aug 20, 2010: Orexo Announces Progress Of Phase I Trial Of OX27 In Cancer Pain
Aug 20, 2010: Orexo Starts Dosing In Phase I Clinical Study Of OX219 In Treating Opioid Addiction
Aug 20, 2010: Orexo To Initiate Phase I Clinical Trial Of OX51 For Treating Intense Pain Episodes In Opioid Tolerant And Opioid-Naive Patients
Dec 19, 2006: Orexo Announces Distribution agreement For Its Pain Product Rapinyl
May 18, 2010: Orexo reports continued strong Abstral sales in Europe
Feb 18, 2009: Orexo signs agreement for Abstral in Israel
Dec 17, 2007: Orexo´s partner Endo announces positive results from interim analysis of Rapinyl phase III clinical trial
Dec 17, 2007: Positive US Phase III Interim Data on Rapinyl Released by Endo Pharmaceuticals Inc
Nov 16, 2010: Orexo announces new sales figures for Abstral from its partner ProStrakan and updates on the US approval
Sep 16, 2010: Orexo signs agreement for Abstral for the Middle East and Africa
Dec 14, 2010: Orexo Reports Positive Phase I Trial Results Of OX219 In Opioid Dependence
Jun 14, 2011: Orexo Announces Successful Completion Of First Clinical Trial With OX27
Jun 14, 2011: Paladin Labs Announces Canadian Launch Of Abstral
Jan 14, 2010: Orexo and Invida jointly announce agreement for Abstral in Asia Pacific
Dec 11, 2008: Abstral Receives Marketing Approval In Germany
Jan 10, 2011: FDA Approval for Abstral (Fentanyl) Sublingual Tablets - US launch planned for Q1 2011
Jan 10, 2011: ProStrakan Receives FDA Approval For Cancer Pain Drug
Jan 10, 2008: Orexo Discloses New Mechanism For Asthma And COPD Treatment
Sep 07, 2010: Update on the FDA review for Abstral
Mar 07, 2008: Rapinyl Receives Swedish Marketing Authorization
Jan 07, 2010: Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe
Sep 06, 2009: ProStrakan Announces FDA Acceptance Of Abstral Filing in the US
Aug 06, 2009: Abstral file submitted to the FDA for approval in the USA
Apr 04, 2011: ProStrakan Launches Abstral In US
Feb 04, 2010: ProStrakan Announces Canadian Regulatory Filing Of Abstral
Sep 02, 2008: Orexo Initiates Clinical Phase II Program For OX914 - A New Product Candidate For The Treatment Of Inflammatory Airway Diseases
Jun 02, 2010: Abstral PDUFA Date Update
Jun 02, 2010: Orexo confirms Abstral PDUFA date update
Mar 02, 2009: Orexo’s Abstral Receives Two Further Large EU Market Approvals In France Aand Spain
Nov 01, 2007: Endo announces update on Phase III-program for Orexo´s pain product Rapinyl
Aug 01, 2007: ProStrakan Launches Nordic Sales Joint Venture with Orexo
Financial Deals Landscape
Orexo AB, Deals Summary
Orexo AB, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Biolipox Acquires Research And Development Assets From Inflazyme Pharmaceuticals
Venture Financing
PharmaKodex Secures $13.43 Million In Series A Financing
Biolipox Secures $41 Million In Series C Financing
Partnerships
Orexo Extends Licensing Agreement With Boehringer
Orexo Enters Into A Co-Development Agreement With Healthcare Company
Orexo Enters Into Co-Marketing Agreement With Hospira
ProStrakan Forms Joint Venture With Orexo
Gedeon Richter Enters Into A Distribution Agreement With Orexo
Doxa Enters Into Co-Development Agreement With Orexo
Licensing Agreements
Orexo Enters Into Licensing Agreement With NovaMed
Orexo Enters Into Licensing Agreement With Invida Group For Abstral
Orexo Enters Into Licensing Agreement With NewBridge Pharmaceuticals For Abstral
Orexo Enters Into Licensing Agreement With Ortho-McNeil-Janssen And Janssen Pharmaceutica
Orexo Enters Into Licensing Agreement With Novartis Pharmaceuticals
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With Orexo
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Endo Pharmaceuticals Enters Into Licensing Agreement With Orexo
Equity Offering
Orexo Completes Rights Issue Of $40 Million
Orexo Completes Initial Public Offering Of $41 Million
Orexo Completes Private Placement Of $7 Million
Debt Offering
Orexo Completes Private Placement Of Convertible Bonds For $15.4 Million
Asset Transactions
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Acquisition
Kibion Acquires Wagner Analysen Technik
Orexo Acquires PharmaKodex
Orexo Acquires Biolipox
Kibion Acquires Noster System
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Orexo AB – Pipeline by Therapy Area and Indication, H2 2011
Orexo AB – Pipeline by Stage of Development, H2 2011
Orexo AB – Monotherapy Products in Pipeline, H2 2011
Orexo AB – Filed, H2 2011
Orexo AB – Phase III, H2 2011
Orexo AB - Phase II, H2 2011
Orexo AB - Phase I, H2 2011
Orexo AB - Pipeline By Therapeutic Class, H2 2011
Orexo AB - Pipeline By Target, H2 2011
Orexo AB – Pipeline By Route of Administration, H2 2011
Orexo AB – Pipeline By Molecule Type, H2 2011
Orexo AB – Recent Pipeline Updates, H2 2011
Orexo AB - Dormant Developmental Projects, 2010
Orexo AB, Subsidiaries
Orexo AB, Deals Summary
Biolipox Acquires Research And Development Assets From Inflazyme Pharmaceuticals
PharmaKodex Secures $13.43 Million In Series A Financing
Biolipox Secures $41 Million In Series C Financing
Orexo Extends Licensing Agreement With Boehringer
Orexo Enters Into A Co-Development Agreement With Healthcare Company
Orexo Enters Into Co-Marketing Agreement With Hospira
ProStrakan Forms Joint Venture With Orexo
Gedeon Richter Enters Into A Distribution Agreement With Orexo
Doxa Enters Into Co-Development Agreement With Orexo
Orexo Enters Into Licensing Agreement With NovaMed
Orexo Enters Into Licensing Agreement With Invida Group For Abstral
Orexo Enters Into Licensing Agreement With NewBridge Pharmaceuticals For Abstral
Orexo Enters Into Licensing Agreement With Ortho-McNeil-Janssen And Janssen Pharmaceutica
Orexo Enters Into Licensing Agreement With Novartis Pharmaceuticals
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Enters Into Licensing Agreement With Orexo
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Boehringer Ingelheim Enters Into Licensing Agreement With Biolipox
Endo Pharmaceuticals Enters Into Licensing Agreement With Orexo
Orexo Completes Rights Issue Of $40 Million
Orexo Completes Initial Public Offering Of $41 Million
Orexo Completes Private Placement Of $7 Million
Orexo Completes Private Placement Of Convertible Bonds For $15.4 Million
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Kibion Acquires Wagner Analysen Technik
Orexo Acquires PharmaKodex
Orexo Acquires Biolipox
Kibion Acquires Noster System
LIST OF FIGURES
Orexo AB – Pipeline by Therapy Area and Indication, H2 2011
Orexo AB – Pipeline by Stage of Development, H2 2011
Orexo AB – Monotherapy Products in Pipeline, H2 2011
Orexo AB – Pipeline By Therapeutic Class, H2 2011
Orexo AB - Pipeline By Target, H2 2011
Orexo AB – Pipeline By Route of Administration, H2 2011
Orexo AB – Pipeline By Molecule Type, H2 2011